Cilt 1 Sağlık Bilimleri

TRİPLE NEGATİF VE HER2 POZİTİF MEME KANSERİNİN KARŞILAŞTIRILMASI

Beyza Özçınar, Sibel OZKAN GURDAL, Gamze CITLAK, Atilla BOZDOGAN, Vahit OZMEN, Abdullah IGCI, Mahmut MUSLUMANOGLU

ÖZ

Amaç: Bu çalışmanın amacı triple negatif meme kanseri (ER-, PR-, Her2-) ile Her2 pozitif meme kanserinin (ER+/-, PR+/-, Her2+) klinkopatolojik özelliklerini karşılaştırmaktır. Hastalar ve Yöntem: Merkezimizde kayıtlı 1822 meme kanseri hastası içerisinden 133 triple negatif ve 160 Her 2 pozitif hastanın dosyaları incelenerek, bu hastaların histopatolojik (tümör boyutu, reseptör durumu, aksilla pozitifliği, histolojik grad, lenfovasküler invazyon varlığı, nekroz ve tümör tipi) ve klinik özellikleri, tedavi modaliteleri ve sağkalım süreleri retrospektif olarak kayıt altına alındı. One way ANOVA, ki-kare, Kaplan Meier testleri kullanılarak istatistiksel analizler yapıldı. P değeri <0.05 anlamlı olarak kabul edildi. Sonuçlar: Her iki grup karşılaştırıldığında Her 2 pozitif grupta lenfovasküler invazyon varlığı (p<0.001), yüksek grad (grad 3) (p=0.003), ve adjuvant kemoterapi oranı (p<0.001), triple negatif grupta ise, lokal yineleme oranı (p=0.032) ve sentinel lenf nodunda mikrometastaz oranı (p=0.009) anlamlı derecede yüksek bulundu. Her 2 pozitif hastalar da non sentinel lenf nodu pozitifliği daha yüksek idi (p<0.001). Her 2 pozitif hastaların 5 yıllık sağkalım oranları %95.6, üçlü negatif alt grubun %92.0 olarak tespit edildi. 5 yıllık hastalıksız sağkalım oranları ise, Her 2 pozitif grupta %85.5, üçlü negatif grupta %82.6 idi. Meme koruyucu cerrahi oranı triple negatif grupta daha fazla idi (p=0.008). Triple negatif grupta lokal yineleme oranı daha fazla olmakla beraber bu durum istatistiksel olarak anlamlı bulunmadı. Tartışma: Triple negatif grupta olan hastaların sağ kalım oranlarının Her 2 pozitif gruba göre daha kötü olduğu görüldü, ancak bu durum istatistiksel olarak anlamlı değildi. Her iki grupta uluslararası literatürdeki ER+, PR+ ve Her2- alt grup ile karşılaştırıldığında daha kötü prognoza sahip idi.

ABSTRACT

Objectives:The aim of this study is to investigate the results of clinicopathological characterics of patients with Her 2 positive (Any ER, any PR status with Her2 +) and triple negative (ER-, PR-, Her2-) subgroups of breast cancer.Patients and Methods: From prospective database of 1822 patients, 133 triple negative patients and 160 Her 2 receptor positive patients’ data collected retrospectively. Clinical, histopathological characteristics (tumor size, tumor receptor status, axillary node involvement, histological grade, lymphovascular invasion, necrosis, tumor type), treatment modalities and survival rateswere recorded. One way ANOVA, chi square and Kaplan Meier tests were used for statistical analysis. P value of <0.05 was accepted as a significant.Results:When we compared the characteristics of both groups, lymphovascular invasion (p<0.001), higher grade (grade 3) (p=0.003), adjuvant chemotherapy (p<0.001) rates were significantly more in Her 2 positive subgroup. Micrometastasis at sentinel lymph node (p=0.009), local recurrence rate (p=0.032) were more significant in triple negative subgroup. Her 2 + patientstend to have more non sentinel lymph node metastasis (p<0.001). 5 years survival of Her 2 positive patients was 95.6%, triple negative patients was 92.0% (p=0.731). 5 years disease free survival rate of Her 2 patients was 85.5% and triple negative patients was 82.6% (p=0.689). Breast conserving surgery rate was more in triple negative group (p=0.008). Triple Ozcinaret al. negative group had much local recurrence than Her2 positive group, but this was notstatistically significant.Conclusion:Tumors with TN subgroup had poorer prognosis than counterparts of Her 2 + group in this study, but this is not significant statistically. Both subgroups have poorer survival than ER+, PR+ and Her2- subgroup of breast cancer patients according to international literature.


Kaynakça
1. Hortobagyi GN, de la Garza SJ, Pritchard K, Amadori D, Haidinger R, Hudis CA, et
al. The global breast cancer burden: variations in epidemiology and survival. Clin
Breast Cancer 2005;6:391-401.
2. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual
report to the nation on the status of cancer. 1975-2002 featuring population based
trends in cancer treatment. J Natl Cancer Inst 2005;97:1407-27.
3. Elston CW, Ellis IO, Pinder SE. Pathological prognostic factors in breast cancer. Crit
Rev Oncol Hematol 1999;31:209-223.
4. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview
of prognostic factors for long term survivors of breast cancer. Breast Cancer Res Treat
2008;107:309-30.
5. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular
protraits of human breast tumors. Nature 2000;406:747-52.
6. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society
of Clinical Oncology 2007 update of recommendations fort he use of tumor markers in
breast cancer. J Clin Oncol 2007;25:5287-312.
7. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and
hormonal therapy for early breast cancer on recurrence and 15 year survival: an
overview of the randomised trials. Lancet 2005;365:1687-1717.
8. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A,Dowsett M, et al. 2 year
follow up of trastuzumab after adjuvant chemotherapy in HER-2 positive breast
cancer: a randomised controlled trial. Lancet 2007;369:29-36.
9. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr, Davidson NE, et al.
Trstuzumab plus adjuvant chemotherapy for operabl HER 2 positive breast cancer. N
Engl J Med 2005;353:1673-84.
10. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al.
Adjuvant docetaxel or vineralbine with or without trasruzumab for breast cancer. N
Engl J Med 2006;354:809-20.
11. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, et al.
Quantitative association between Her -2/ neu and steroid hormone receptors in
hormone receptor positive primary breast cancer. J Natl Cancer Inst 2003;95:142-53.
12. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer.
Breast Cancer Res 2004;6:109-18.
13. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the
human c-erB-2 gene: a 185 kilodalton glycoprotein with tyrosine kinase activity.
Science 1986;232:1644-46.
14. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast
cancer: correlation of relapse ans survival with amplications of the Her-2 oncogene.
Science 1987;235:177-82.
15. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of
the HER-2 protooncogene in human breast and ovarian cancer. Science 1989;244:707-
12.
16. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, et al. Pathologic findings
from the National Surgical Adjuvant Breast and Bowel Project: prognostic
significance of eerB-2 protein overexpression in primary breast cancer. J Clin Oncol
1990;8:103-12.
17. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The HER-2 gene and
protein in breast cancer 2003: biomarker and target of therapy. Rev Oncologist
2003;8:307-25.
18. Rakha EA, Ellis IO. Triple negative breast cancer: review. Pathology 2009;41:40-7.
Corresponding Author:
Beyza Ozcinar MD.
Istanbul University, Istanbul Medical Faculty,
General Surgery Department
Capa, 34093
Istanbul-TURKEY
Phone number: 00 90 532 711 9316
Fax numebr: 00 90 212 534 0210
Email: drbeyza@hotmail.com
Konular
Diğer ID JA24VZ85HV
Dergi Bölümü Araştırma Makalesi
Yazarlar

Yazar: Beyza Özçınar

Yazar: Sibel OZKAN GURDAL

Yazar: Gamze CITLAK

Yazar: Atilla BOZDOGAN

Yazar: Vahit OZMEN

Yazar: Abdullah IGCI

Yazar: Mahmut MUSLUMANOGLU

Bir cevap yazın

E-posta hesabınız yayımlanmayacak. Gerekli alanlar * ile işaretlenmişlerdir